Ceritinib
Added to RFQ
For Research & Analytical Purposes. Not for Personal use.
Packaging & Handling
Indicative product packaging is shown for visual reference. Actual packaging may vary based on pack size, quantity, storage condition and shipping requirements.
Documentation Available
Detailed specifications, certificates, and supporting documents are available upon request.
Detailed specifications, certificates, and supporting documents are available upon request.
Storage: Refer MSDS for complete information.
Hazard: Refer MSDS for accurate information.
Ceritinib Product Information
Ceritinib is listed under API and is intended for analytical research, quality control and pharmaceutical reference standard applications. It is associated with Ceritinib. The product is supplied by Clearsynth under CAT No. CS-O-11185.
Clearsynth provides this compound for research and analytical use, with product information including CAS number, molecular formula, molecular weight and product enquiry details.
Technical Data
Product Name
Ceritinib
CAS No.
1032900-25-6
CAT No.
CS-O-11185
HSN Code
38229010
Country of Origin
Can be shipped from India, Canada and USA
Molecular Formula
C28H36ClN5O3S
Molecular Weight
558.14
Category
API Family
Storage Condition
Refer MSDS for complete information.
Hazard Compound
Refer MSDS for accurate information.
Description
Regulatory Description
Ceritinib is supplied with detailed characterization data compliant with regulatory guideline. Ceritinib can be used for analytical method development, method validation (AMV), Quality Control (QC) application for Abbreviated New Drug Application (ANDA), or during commercial production of Ceritinib.
Overview
Ceritinib is used for the treatment of adults with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) following failure (secondary to resistance or intolerance) of prior crizotinib therapy.
Synonyms
Ceritinib
Application Notes
Ceritinib is used for the treatment of adults with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) following failure (secondary to resistance or intolerance) of prior crizotinib therapy.
Product Applications & Regulatory Search Terms
Useful product, supplier and regulatory search terms for this reference standard.